Pierre Armand Morgon

Dr. Pierre Armand Morgon is a Chairman at Kupando GmbH, a Non-Executive Chairman at Adiposs SA, a Chairman at MYCB1 BV, a Chairman at MYCB1 Group BV, an Independent Non-Executive Director at Barinthus Biotherapeutics Plc, a CEO and Founder at Mrgn Advisors, a CEO at Drug Abuse Sciences, an Advisor at CUBE Labs Srl, a Chairman at Health Technology Holding Srl, a Chief Executive Officer at Ibex Therapeutics SA, a Chief Executive Officer & Manager at MRGN Advisors SARL and an Independent Non-Executive Director at Limula SA. He is on the Board of Directors at Univercells SA, Barinthus Biotherapeutics Plc, International Association for Biologicals, Zambon Biotech SA and Limula SA. Dr. Morgon was previously employed as an Independent Non-Executive Director by Amoéba SA, an Executive VP-Portfolio Strategy & Head-Europe by CanSino Biologics, Inc., a Non-Executive Director by Vaccitech (UK) Ltd., a Chairman by Alma Biotherapeutics, a Chairman by Virometix AG, a Chief Executive Officer by AJ Biologics Sdn.
Bhd., a Chairman by Eurocine Vaccines AB, a Chairman by Theradiag SA, a VP-Franchise & Global Marketing Strategy by Sanofi Pasteur SA, a Chief Operating Officer by Onxeo SA, and a Marketing Director by Cegedim SA. He also served on the board at Schering-Plough SAS. He received his undergraduate degree from INSEAD, an undergraduate degree from the International Institute for Management Development, a graduate degree from Jean Moulin University Law School, an MBA from ESSEC Business School and a doctorate degree from the University of Lyon.